Episode 10, “Revisiting Seamless 2/3 Trial for GLP-1 Agonist"
In the latest episode of "In the Interim..." we dissect the intricacies and breakthroughs of the groundbreaking AWARD-5 trial for Eli Lilly’s dulaglutide, now known as Trulicity. Discover how we overcame design challenges, integrated innovative statistical methods, and navigated regulatory hurdles.
𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
—Seamless Phase 2/3 trial integration for GLP-1 Agonist
—Intricacies of Bayesian algorithms and adaptive randomization
—Collaborative efforts between Berry Consultants, Eli Lilly, and regulatory bodies
This episode is a must-listen for anyone involved in clinical trial design or interested in cutting-edge statistical approaches. Don't miss it! https://www.berryconsultants.com/resource/10-revisiting-seamless-2-3-trial-for-glp-1-agonist